BioSpace News Archive

The lawsuit, brought by Arbutus Biopharma, marks the latest legal action in an ongoing battle for intellectual property underlying mRNA vaccines for COVID-19.

New therapeutics for Major Depressive Disorder could change the treatment landscape and give patients more options.

Liver toxicities triggered a partial clinical hold on Merck KGaA’s trial studying its BTK inhibitor candidate for multiple sclerosis.

The company has several targeted therapeutics in early-stage trials and preclinical development for cancer types with high expression levels of the protein.

The new partnership involves an initial payout of $75 million and the potential for up to $2.6 billion in milestone funding.

Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, May 4, 2023, at 8:00 a.m. ET to report its first quarter 2023 financial results and other business highlights.

Krystal Biotech, Inc. announced today that the Company will be presenting new data on the compassionate use of topical beremagene geperpavec (B-VEC) to treat a patient with dystrophic epidermolysis bullosa (DEB) with recurrent cicatrizing conjunctivitis at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting being held from April 23-27, 2023 in New Orleans, LA.

Merck announced the U.S. FDA has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Clinical Laserthermia Systems Americas, Inc. today announced a research collaboration agreement between the National Institutes of Health Clinical Center (NIHCC) and its parent company, Clinical Laserthermia Systems AB, based in Sweden.

Candesant Biomedical today announced the U.S. Food and Drug Administration (FDA) granted a de novo request for Brella™, the first and only 3-Minute SweatControl Patch™ for the reduction of excessive underarm sweating in adults with primary axillary hyperhidrosis.